About Non-structural maintenance of chromosomes element 1 homolog
Non-structural maintenance of chromosomes element 1 homolog (NSMCE1) is a protein
from Homo sapiens identified by UniProt accession
Q8WV22, 266 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Non-structural maintenance of chromosomes element 1 homolog |
|---|
| UniProt accession | Q8WV22 |
|---|
| Gene | NSMCE1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 266 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- traffic air pollution measurement · score 0.23
- peripheral arterial disease · score 0.23
- endometrial cancer · score 0.23
- breast adenocarcinoma · score 0.23
- Inhalant adrenergic use measurement · score 0.22
- gut microbiome measurement · score 0.18
- taxonomic microbiome measurement · score 0.18
- asthma · score 0.16
- esophageal cancer · score 0.14
- eosinophil count · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WV22-F1 | alphafold | PREDICTED | 89.21 | — |
Amino-acid sequence (266 residues)
MQGSTRRMGV MTDVHRRFLQ LLMTHGVLEE WDVKRLQTHC YKVHDRNATV DKLEDFINNI NSVLESLYIE IKRGVTEDDG RPIYALVNLA TTSISKMATD FAENELDLFR KALELIIDSE TGFASSTNIL NLVDQLKGKK MRKKEAEQVL QKFVQNKWLI EKEGEFTLHG RAILEMEQYI RETYPDAVKI CNICHSLLIQ GQSCETCGIR MHLPCVAKYF QSNAEPRCPH CNDYWPHEIP KVFDPEKERE SGVLKSNKKS LRSRQH
Explore Non-structural maintenance of chromosomes element 1 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets